IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

HW

re Application of AZARE, et al.

Application No.: 10/849,089

Filed: 05/19/2004

Title: Azaindole-derivatives as factor Xa inhibitors

Examiner:

R. T. Shiao

Art Unit:

1626

I hereby certify that this correspondence is being deposited with the United States Postal Service as First Class Mail in an envelope addressed to Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on

December 6, 2005
Date of Deposit

Cionature

<u>SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT</u> <u>UNDER 37 C.F.R. 1.56, 1.97 AND 1.98</u>

Commissioner for Patents P. O. Box 1450 Alexandria, VA 22313-1450

Applicants submit herewith patents, publications, and other information of which they are aware, which they believe may be material, as defined in 37 C.F.R. 1.56(b), to the examination of this application and in respect of which there may be a duty to disclose in accordance with 37 C.F.R. 1.56(a). While the information referred to in this Information Disclosure Statement may be material pursuant to 37 C.F.R. 1.56(b), the filing of this Information Disclosure Statement is not intended to, pursuant to 37 C.F.R. 1.97(h), constitute an admission that any patent, publication or other information referred to is, or is considered to be, material to the patentability of this invention. Pursuant to 37 C.F.R. 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information exists.

(a) This Information Disclosure Statement is filed within the period set forth in §1.97(b) because it accompanies the new patent application submitted herewith, is filed within three months of the filing date of a national application or within three months of the date of entry of the national stage as set forth in §1.491 in an international application, or is believed to be filed before the mailing date of a first Office Action on the merits, whichever event occurs last. However, in the event that the first office action has been mailed, the Commissioner is authorized to charge any fees under 37 C.F.R. 1.17(p) or credit any overpayment to Account No. 18-1982.

 1.97(b), but is believed to be filed before the mailing date of a final action under §1.1 or a notice of allowance under §1.311, whichever occurs first. (1) The undersigned attorney certifies that each item of information contained in this
<u></u>
(1) The undersigned attorney certifies that each item of information contained in thi
Information Disclosure Statement was cited in a communication from a foreign
patent office in a counterpart foreign application not more than three months pri
to the filing of this statement;
(2) The undersigned attorney certifies that no item of information contained in this
Information Disclosure Statement was cited in a communication from a foreign
patent office in a counterpart foreign application or, to the knowledge of the
undersigned attorney after making reasonable inquiry, was known to any
individual designated in §1.56(c) more than three months prior to the filing of the
statement; or
(3) This Information Disclosure Statement is accompanied by a transmittal letter in
which payment of the fee set forth in §1.17(p) and required by 37 C.F.R. 1.97(c)
authorized.

Respectfully submitted,

Joseph Rossi, Reg. No. 47,038

Attorney for Applicant

Aventis Pharmaceuticals Inc.
Patent Department
Route #202-206 / P.O. Box 6800
Bridgewater, NJ 08807-0800
Telephone (908) 231-3410
Telefax (908) 231-2626

Aventis Docket No. DEAV2003/0033 US NP

Please	tvne a	nhie	sion	/+\	insida	thic	hov	->	\Box
1 10030	type a	pius	SIGH	(7)	1112106	นแร	UUX	_	

PTO/SB/08A (10-96)
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Apploved for use first frought locations from the Apploved for use first frought locations from the Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

OFF OF SAME

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 1

Complete if Known				
Application Number	10/849,089	_		
Filing Date	05-19-2004			
First Named Inventor	NAZARÉ			
Group Art Unit	1626			
Examiner Name	R. T. Shiao	_		
Attorney Docket Number	DEAV2003/0033 - US - NP			

	U.S. PATENT DOCUMENTS							
Examiner Initials*	Cite No.1	U.S. Patent Number	Document Kind Code ² (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear		
		09/794,214		ZHU, et al.	02-28-2001	-		
		10/326,005		CASTELHANO, et al.	12-20-2002			
		10/510,046		CEZANNE, et al.	10-01-2004			
		6,140,351		ARNAIZ, et al.	10-31-2000			
		6,790,853		JACOBSON, et al.	09-14-2004			
		<u> </u>						
j l		1						

	FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No.1	Foreign Patent Document Office ³ Number ⁴ Kind Code ⁵ (if known)			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		JP	2004203791A (abstract		MAKOTO, et al.	07-22-2004		
		JP	2004210716A(abstrac	6)	HIDEYUKI, et al.	07-29-2004		
		wo	02/00651		QUAN, et al.	01-03-2002		
		wo	01/19788		ZHU,B.	03-22-2001		
								↓
								ـــــ
				_	<u>.</u>			igspace
								├ ─
		<u> </u>		_				₩
		l		ı				Ш

Examiner	 Date	
Signature	 Considered	

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.